Interleukin-6 serum level and -597 A/G gene polymorphism in moderate and severe chronic obstructive pulmonary disease

Inflammation is a major pathogenic pathway in pulmonary chronic obstructive disease (COPD). Interleukin-6 (IL-6) mediates the local and systemic immune response. The aim consisted in investigating the relationship between IL-6 serum levels and IL-6 -597A/G gene polymorphism (rs1800797) with COPD. Se...

Full description

Bibliographic Details
Main Authors: Ana Florica Chiș, Andreea Cătană, Olga Sorițău, Bogdan Augustin Chiș, Ancuța Cutaș, Carmen Monica Pop
Format: Article
Language:English
Published: SAGE Publishing 2020-10-01
Series:European Journal of Inflammation
Online Access:https://doi.org/10.1177/2058739220966469
id doaj-d58c5a2393244ecea700e182d6f439fe
record_format Article
spelling doaj-d58c5a2393244ecea700e182d6f439fe2020-11-25T03:53:05ZengSAGE PublishingEuropean Journal of Inflammation2058-73922020-10-011810.1177/2058739220966469Interleukin-6 serum level and -597 A/G gene polymorphism in moderate and severe chronic obstructive pulmonary diseaseAna Florica Chiș0Andreea Cătană1Olga Sorițău2Bogdan Augustin Chiș3Ancuța Cutaș4Carmen Monica Pop5“Leon Daniello” Clinical Hospital of Pneumology, Cluj-Napoca, RomaniaDepartment of Molecular Sciences, “Iuliu Haţieganu” University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania“Ion Chiricuţă” Oncological Institute Cluj-Napoca, Cluj-Napoca, Romania2nd Department of Internal Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Medical Informatics, “Iuliu Haţieganu” University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania“Leon Daniello” Clinical Hospital of Pneumology, Cluj-Napoca, RomaniaInflammation is a major pathogenic pathway in pulmonary chronic obstructive disease (COPD). Interleukin-6 (IL-6) mediates the local and systemic immune response. The aim consisted in investigating the relationship between IL-6 serum levels and IL-6 -597A/G gene polymorphism (rs1800797) with COPD. Serum levels of IL-6 were determined using an enzyme-linked immune-sorbent assay, in 120 participants (60 COPD patients and 60 healthy subjects), from Transylvanian region. The IL-6 -597A/G gene polymorphism was investigated by high molecular weight genomic DNA extracted from the peripheral blood leukocytes, and subsequently analyzed by the Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) technique. Smoking history, the severity of the disease, expressed by the GOLD stages, and arterial blood partial pressure of oxygen (PaO 2 ) levels were also investigated. COPD patients had significantly elevated blood levels of IL-6 when compared to the control group ( p  < 0.05). The frequencies of AA, AG, and GG genotypes were 61.6%, 26.6%, and 11.6% in the COPD cases and 70%, 23.3%, and 6.7% in healthy subjects, respectively. There were no statistically significant differences in IL-6 rs1800797 genotypes and allele frequencies between cases and controls ( χ 2  = 0.54, OR = 1.29 and χ 2  = 0.21, OR = 1.48, respectively). Higher serum levels of IL-6 were found in the GG genotype subgroup in COPD patients. IL 6 levels are higher in COPD patients, where positively correlate with pack-year index, but not with clinical features. Although COPD patients did not have statistically different rs1800797 allele distribution compared to healthy subjects, the GG genotype is associated with higher IL6 serum levels.https://doi.org/10.1177/2058739220966469
collection DOAJ
language English
format Article
sources DOAJ
author Ana Florica Chiș
Andreea Cătană
Olga Sorițău
Bogdan Augustin Chiș
Ancuța Cutaș
Carmen Monica Pop
spellingShingle Ana Florica Chiș
Andreea Cătană
Olga Sorițău
Bogdan Augustin Chiș
Ancuța Cutaș
Carmen Monica Pop
Interleukin-6 serum level and -597 A/G gene polymorphism in moderate and severe chronic obstructive pulmonary disease
European Journal of Inflammation
author_facet Ana Florica Chiș
Andreea Cătană
Olga Sorițău
Bogdan Augustin Chiș
Ancuța Cutaș
Carmen Monica Pop
author_sort Ana Florica Chiș
title Interleukin-6 serum level and -597 A/G gene polymorphism in moderate and severe chronic obstructive pulmonary disease
title_short Interleukin-6 serum level and -597 A/G gene polymorphism in moderate and severe chronic obstructive pulmonary disease
title_full Interleukin-6 serum level and -597 A/G gene polymorphism in moderate and severe chronic obstructive pulmonary disease
title_fullStr Interleukin-6 serum level and -597 A/G gene polymorphism in moderate and severe chronic obstructive pulmonary disease
title_full_unstemmed Interleukin-6 serum level and -597 A/G gene polymorphism in moderate and severe chronic obstructive pulmonary disease
title_sort interleukin-6 serum level and -597 a/g gene polymorphism in moderate and severe chronic obstructive pulmonary disease
publisher SAGE Publishing
series European Journal of Inflammation
issn 2058-7392
publishDate 2020-10-01
description Inflammation is a major pathogenic pathway in pulmonary chronic obstructive disease (COPD). Interleukin-6 (IL-6) mediates the local and systemic immune response. The aim consisted in investigating the relationship between IL-6 serum levels and IL-6 -597A/G gene polymorphism (rs1800797) with COPD. Serum levels of IL-6 were determined using an enzyme-linked immune-sorbent assay, in 120 participants (60 COPD patients and 60 healthy subjects), from Transylvanian region. The IL-6 -597A/G gene polymorphism was investigated by high molecular weight genomic DNA extracted from the peripheral blood leukocytes, and subsequently analyzed by the Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) technique. Smoking history, the severity of the disease, expressed by the GOLD stages, and arterial blood partial pressure of oxygen (PaO 2 ) levels were also investigated. COPD patients had significantly elevated blood levels of IL-6 when compared to the control group ( p  < 0.05). The frequencies of AA, AG, and GG genotypes were 61.6%, 26.6%, and 11.6% in the COPD cases and 70%, 23.3%, and 6.7% in healthy subjects, respectively. There were no statistically significant differences in IL-6 rs1800797 genotypes and allele frequencies between cases and controls ( χ 2  = 0.54, OR = 1.29 and χ 2  = 0.21, OR = 1.48, respectively). Higher serum levels of IL-6 were found in the GG genotype subgroup in COPD patients. IL 6 levels are higher in COPD patients, where positively correlate with pack-year index, but not with clinical features. Although COPD patients did not have statistically different rs1800797 allele distribution compared to healthy subjects, the GG genotype is associated with higher IL6 serum levels.
url https://doi.org/10.1177/2058739220966469
work_keys_str_mv AT anafloricachis interleukin6serumleveland597aggenepolymorphisminmoderateandseverechronicobstructivepulmonarydisease
AT andreeacatana interleukin6serumleveland597aggenepolymorphisminmoderateandseverechronicobstructivepulmonarydisease
AT olgasoritau interleukin6serumleveland597aggenepolymorphisminmoderateandseverechronicobstructivepulmonarydisease
AT bogdanaugustinchis interleukin6serumleveland597aggenepolymorphisminmoderateandseverechronicobstructivepulmonarydisease
AT ancutacutas interleukin6serumleveland597aggenepolymorphisminmoderateandseverechronicobstructivepulmonarydisease
AT carmenmonicapop interleukin6serumleveland597aggenepolymorphisminmoderateandseverechronicobstructivepulmonarydisease
_version_ 1724480009188409344